APO-DICLOFENAC OPHTHALMIC SOLUTION

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

DICLOFENAC SODIUM

Saadav alates:

APOTEX INC

ATC kood:

S01BC03

INN (Rahvusvaheline Nimetus):

DICLOFENAC

Annus:

0.1%

Ravimvorm:

SOLUTION

Koostis:

DICLOFENAC SODIUM 0.1%

Manustamisviis:

OPHTHALMIC

Ühikuid pakis:

2.5/5/10ML FILL

Retsepti tüüp:

Prescription

Terapeutiline ala:

NONSTEROIDAL ANTI-INFLAMMATORY AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0114417004; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2015-05-12

Toote omadused

_APO-DICLOFENAC OPHTHALMIC (Diclofenac Sodium Ophthalmic Solution)_
_Page 1 of 28_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
APO-DICLOFENAC OPHTHALMIC
Diclofenac Sodium Ophthalmic Solution
Ophthalmic solution, 0.1% w/v for Topical use
Anti-inflammatory agents, non-steroids
APOTEX INC.
150 Signet Drive
Toronto, Ontario
M9L 1T9
Date of Initial Authorization:
MAY 12, 2015
Date of Revision:
SEP 18, 2023
Submission Control Number: 275184
_APO-DICLOFENAC OPHTHALMIC (Diclofenac Sodium Ophthalmic Solution)_
_Page 2 of 28_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male
Potential
09/2023
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
09/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS ...........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS ...........................................................................................................
4
1.1
Pediatrics
...........................................................................................................
4
1.2
Geriatrics
...........................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
................................................... 4
4.4
Administration
...................................................................................................
5
4.5
Missed Dose
..........................